A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
Public ClinicalTrials.gov record NCT00735475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
Study identification
- NCT ID
- NCT00735475
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,268 participants
Conditions and interventions
Conditions
Interventions
- CSL Limited Influenza Virus Vaccine (Afluria®) Biological
- US Licensed Influenza Virus Vaccine (Fluzone®) Biological
Biological
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2008 (Type not available)
- Primary completion
- Jan 2009 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- May 23, 2018
2008 – 2009
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Central Arkansas Medical Association | Mountain Home | Arkansas | 72635 | — |
| Covance CRU, Inc | Boise | Idaho | 83704 | — |
| The University of Iowa | Iowa City | Iowa | 52242 | — |
| Kentucky Pediatric/ Adult Research | Bardstown | Kentucky | 40004 | — |
| Saint Louis University Medical Center | St Louis | Missouri | 63104 | — |
| University of Rochester School of Medicine and Dentistry | Rochester | New York | 14642 | — |
| Duke University Medical Center | Durham | North Carolina | 27704 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Covance CRU, Inc. | Portland | Oregon | 97239 | — |
| Primary Physicians Research, Inc. | Pittsburgh | Pennsylvania | 15241 | — |
| Clinical Partners, LLC | Johnston | Rhode Island | 02919 | — |
| Vanderbilt Medical Center | Nashville | Tennessee | 37232 | — |
| Covance CRU Inc. | Austin | Texas | 78752 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00735475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2018 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00735475 live on ClinicalTrials.gov.